Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

544.92 -15.98 (-2.85%)
Streaming Delayed Price Updated: 11:57 AM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Why Is Dutch Pharma Argenx Trading Lower Today?
Tuesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADVANCE-SC study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with primary immune thrombocytopenia... 
Via Benzinga
Argenx Stock Crashes On An Unexpected Failure For Its Biggest Drug
The company was hoping its drug would make a difference for patients with a rare blood disorder. 
Via Investor's Business Daily
These 2 Stocks Are Falling in a Fading Rally
It's been a good month, but the stock market's looking tired. 
Via The Motley Fool
Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults... 
Via Benzinga
Exposures Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers for Tuesday morning with all of the latest news you need to know today! 
Via InvestorPlace
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $5,000 Today
Via Benzinga
Zscaler Posts Q1 Results, Joins argenx, Cool Company And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded mixed this morning, with the Dow Jones futures gaining around 15 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
From argenx SE
Via GlobeNewswire
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the  
Via Benzinga
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
Earnings Outlook For argenx
Via Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
Tech Titans Rising: 7 Underrated Stocks Set for Explosive Growth
Are you looking to invest in rising tech stocks? Here are seven underrated stocks set for explosive growth. 
Via InvestorPlace
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
From argenx SE
Via GlobeNewswire
The Latest Analyst Ratings for argenx
Via Benzinga
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
Argenx Comes Up With Big Sales Beat, Narrower-Than-Expected Losses
The company sells Vyvgart, a treatment for generalized myasthenia gravis. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
From argenx SE
Via GlobeNewswire
Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review
But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus. 
Via Investor's Business Daily
What's Going On Pfizer's Subsidiary Biohaven Stock?
Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an  
Via Benzinga
Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%
The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases. 
Via Investor's Business Daily
Why Immunovant Stock Is Bolting Higher Today
The company may have best-in-class autoimmune disease therapy under its roof. 
Via The Motley Fool
Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering
Both companies are working on drugs that lower an antibody tied to numerous autoimmune conditions. 
Via Investor's Business Daily
Immunovant Soars 73% — And Slugs Argenx — As Autoimmune Disease Battle Heats Up
Immunovant is hoping to come up with the best drug in its class, lowering a key antibody tied to autoimmune diseases. 
Via Investor's Business Daily
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback